JP7846501B2 - 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物 - Google Patents

眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物

Info

Publication number
JP7846501B2
JP7846501B2 JP2020529733A JP2020529733A JP7846501B2 JP 7846501 B2 JP7846501 B2 JP 7846501B2 JP 2020529733 A JP2020529733 A JP 2020529733A JP 2020529733 A JP2020529733 A JP 2020529733A JP 7846501 B2 JP7846501 B2 JP 7846501B2
Authority
JP
Japan
Prior art keywords
acid
pharmaceutically acceptable
salt
retinal
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505554A5 (https=
JP2021505554A (ja
Inventor
ノルテス，シャビエル カプデビラ
アキルエ，ハビエル サンアグスティン
ガニャン，マリア イサベル デルガド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Publication of JP2021505554A publication Critical patent/JP2021505554A/ja
Publication of JP2021505554A5 publication Critical patent/JP2021505554A5/ja
Application granted granted Critical
Publication of JP7846501B2 publication Critical patent/JP7846501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020529733A 2017-12-04 2018-11-29 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物 Active JP7846501B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382832.8 2017-12-04
EP17382832 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (3)

Publication Number Publication Date
JP2021505554A JP2021505554A (ja) 2021-02-18
JP2021505554A5 JP2021505554A5 (https=) 2022-01-06
JP7846501B2 true JP7846501B2 (ja) 2026-04-15

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529733A Active JP7846501B2 (ja) 2017-12-04 2018-11-29 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物

Country Status (24)

Country Link
US (1) US20200390729A1 (https=)
EP (1) EP3720428B1 (https=)
JP (1) JP7846501B2 (https=)
KR (1) KR102756155B1 (https=)
CN (1) CN111542316A (https=)
AU (1) AU2018378981B2 (https=)
BR (1) BR112020011160A2 (https=)
CA (1) CA3083835A1 (https=)
CL (1) CL2020001426A1 (https=)
DK (1) DK3720428T3 (https=)
ES (1) ES2941036T3 (https=)
FI (1) FI3720428T3 (https=)
HR (1) HRP20230319T1 (https=)
HU (1) HUE061852T2 (https=)
MA (1) MA50991B1 (https=)
MX (1) MX2020005809A (https=)
MY (1) MY205498A (https=)
PH (1) PH12020550722A1 (https=)
PL (1) PL3720428T3 (https=)
PT (1) PT3720428T (https=)
SG (1) SG11202004940VA (https=)
SI (1) SI3720428T1 (https=)
WO (1) WO2019110416A1 (https=)
ZA (1) ZA202003944B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN117257963B (zh) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途
CN117643573B (zh) * 2024-01-29 2024-05-03 天津医科大学眼科医院 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777699A1 (en) 2012-02-02 2014-09-17 Luis Antonio Outeirino Miguez Use of 2,5-dihydroxbencene sulfonic acid (dobesilate) for the treatment of age-related macular degeneration
JP2015500213A (ja) 2011-11-30 2015-01-05 ザイジェン インフラメーション リミテッド 眼乾燥症候群を処置するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
JP2015510759A (ja) 2012-03-05 2015-04-13 ウェイン・ステート・ユニバーシティー チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
EP2875811A1 (en) 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages
JP2015515487A (ja) 2012-04-24 2015-05-28 スロンボジェニックス エヌ．ブイ． 抗ｐｄｇｆ−ｃ抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500213A (ja) 2011-11-30 2015-01-05 ザイジェン インフラメーション リミテッド 眼乾燥症候群を処置するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP2777699A1 (en) 2012-02-02 2014-09-17 Luis Antonio Outeirino Miguez Use of 2,5-dihydroxbencene sulfonic acid (dobesilate) for the treatment of age-related macular degeneration
JP2015510759A (ja) 2012-03-05 2015-04-13 ウェイン・ステート・ユニバーシティー チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2015515487A (ja) 2012-04-24 2015-05-28 スロンボジェニックス エヌ．ブイ． 抗ｐｄｇｆ−ｃ抗体
EP2875811A1 (en) 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Also Published As

Publication number Publication date
SI3720428T1 (sl) 2023-05-31
CA3083835A1 (en) 2019-06-13
ES2941036T3 (es) 2023-05-16
EP3720428A1 (en) 2020-10-14
WO2019110416A1 (en) 2019-06-13
KR102756155B1 (ko) 2025-01-20
KR20200096569A (ko) 2020-08-12
ZA202003944B (en) 2022-12-21
PH12020550722A1 (en) 2021-02-15
CN111542316A (zh) 2020-08-14
HRP20230319T1 (hr) 2023-05-12
CL2020001426A1 (es) 2020-11-06
AU2018378981A1 (en) 2020-07-16
EP3720428B1 (en) 2023-01-11
BR112020011160A2 (pt) 2020-11-17
MX2020005809A (es) 2020-08-20
HUE061852T2 (hu) 2023-08-28
DK3720428T3 (da) 2023-03-20
US20200390729A1 (en) 2020-12-17
JP2021505554A (ja) 2021-02-18
MA50991B1 (fr) 2023-03-31
FI3720428T3 (fi) 2023-03-30
MA50991A (fr) 2020-10-14
PT3720428T (pt) 2023-04-03
PL3720428T3 (pl) 2023-05-08
MY205498A (en) 2024-10-23
SG11202004940VA (en) 2020-06-29
AU2018378981B2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
CN111629720A (zh) 用于治疗眼科病况的组合物和方法
JP7846501B2 (ja) 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物
Nagai et al. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles
US10357453B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP2018512452A (ja) エンドセリン受容体の拮抗薬の局所用眼科製剤およびそれらの使用
CA2808628A1 (en) Ophthalmic formulations of squalamine
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
US20200171124A1 (en) Topical compositions for ophthalmic and otic use
WO2025261323A1 (zh) 一种依维莫司眼局部给药制剂
AU2020299145B2 (en) Compositions and methods for treating eye diseases
US11045435B2 (en) Methods for treating ocular diseases
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
HK40036612A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
HK40036612B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
WO2006098292A1 (ja) 眼疾患治療剤
CN121969352A (zh) 用于局部眼部使用的凝胶制剂
US20240108632A1 (en) Pharmaceutical composition for administration as ophthalmic drop to patient requiring optic nerve protection
TWI766565B (zh) 用於治療眼疾的組合物及其用途
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
JPH10203979A (ja) チアプロフェン酸を含有する抗眼炎症剤
WO2026078034A1 (en) Sitagliptin for use in retinal diseases with neovascularization
AU2015258244C1 (en) Ophthalmic formulations of squalamine
JP2741285B2 (ja) 緑内障治療剤
CN117355292A (zh) 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物
JPH08231393A (ja) 眼局所用アレルギー性結膜炎治療剤

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230830

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846501

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150